Skip to main content

Table 1 Baseline characteristics of heart transplant recipients included in the study

From: Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections

  No VAD (n = 84) VAD (n = 35)
Follow-up, years; mean (SD) 1.38 (1.07) 1.31 (1.06)
Recipient age, years; mean (SD) 47.9 (16.9) 45.7 (16.7)
Recipient gender, male; n (%) 62 (73.8) 28 (80)
Donor age, years; mean (SD) 41.3 (16.5) 40.7 (15.0)
Donor gender, male; n (%) 48 (57.1) 24 (68.6)
Prior diabetes; n (%) 15 (17.9) 4 (11.4)
BMI, kg/m2; mean (SD) 24.4 (4.7) 25.2 (4.8)
Serum creatinine, umol/l; mean (SD) 125.9 (66.0) 103.3 (47.1)
Underlying disease; n (%)   
 - Cardiomyopathy
 - Ischemic
 - Congenital heart disease
 - Other
41 (48.8)
23 (27.4)
5 (5.9)
15 (17.9)
18 (51.4)
12 (34.3)
1 (2.9)
4 (11.4)
Cold ischemia, min; mean (SD) 151 (54.3) 164 (54.4)
Bypass time, min; mean (SD) 168 (65.6) 186 (71.1)
Induction therapy; n (%)   
 - Basiliximab
 - ATG
 - None
7 (8.3)
71 (84.5)
6 (7.1)
6 (17.1)
24 (68.6)
5 (14.3)
Maintenance at discharge; n (%)   
 - Tacrolimus
 - Cyclosporin
 - MMF/MPA
 - Azathioprine
 - Everolimus
 - Steroids
28 (33.3)
39 (46.4)
63 (75.0)
21 (25.0)
9 (10.7)
74 (88.1)
10 (28.6)
13 (37.1)
22 (62.9)
7 (20.0)
3 (8.6)
27 (77.1)
  1. There were no significant differences between the two groups. VAD ventricular-assist device, BMI body mass index, ATG anti-thymocyte globulin, MMF mycophenolate mofetil, MPA mycophenolic acid